Evidence map›Paper›PMID 40163296›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Structural Biology for Target Identification and Validation.

Yuliya Dubianok, Anand Kumar, Alexey Rak

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. How many crystal structures do you need to trust your docking results?bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuliya Dubianok *Sanofi R&D, Bio Structure and Biophysics at Integrated Drug Discovery, Vitry-sur-Seine, France.
Anand Kumar *Sanofi R&D, Bio Structure and Biophysics at Integrated Drug Discovery, Vitry-sur-Seine, France.
Alexey RakSanofi R&D, Bio Structure and Biophysics at Integrated Drug Discovery, Vitry-sur-Seine, France. Alexey.rak@sanofi.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structural biology is catalyzing a paradigm shift in drug discovery towards rational approaches in target identification and validation. Leveraging structural insights obtained through cryo-EM or X-ray crystallography not only enhances the efficiency of drug discovery projects in terms of time and cost, but also significantly improves the likelihood of achieving market approval.Initiating a successful project necessitates more than just a robust package for target credentialing; it demands a comprehensive strategy for the identification and optimization of potential drugs. The critical evaluation of target druggability is markedly enhanced when supported by experimentally derived structural information. This nuanced approach ensures a more thorough understanding of the technical feasibility of drug development from the project's inception.

Indexed as

Drug DiscoveryProteinsCryoelectron MicroscopyCrystallography, X-RayHumansProteinsArtificial intelligence (AI)Cryogenic electron microscopy (cryo-EM)Crystallographic fragment screeningDrug discovery (DD)Fragment-based drug discovery (FBDD)Single particle analysis (SPA)Structural biologyTarget identification and validation (TidVal)X-ray crystallography (X-ray)

Identifiers

PMID40163296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.